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were discounted at 3.5%. The base case analysis used a conservative estimate of 80 kg  
for the patient. Uncertainty around the cost effectiveness estimates was explored using          
one-way and probabilistic sensitivity analysis. RESULTS: Inﬂiximab verses ciclosporin   
resulted in an ICER of £19,290 while inﬂiximab therapy dominated standard care and 
surgery treatment options. Changing the utility estimates, medium term ciclosporin 
colectomy probability, and long term treatment effect results in the ICER values being 
above the cost effectiveness threshold of £30,000 per QALY. CONCLUSIONS: 
 Inﬂiximab can be considered as a cost effective treatment compared to standard            
care in patients with severely active ulcerative colitis (UC) hospitalised with an acute 
exacerbation in Scotland.
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OBJECTIVES: To estimate resource utilization and direct medical cost of chronic 
hepatitis C (CHC) from a Thai payer perspective. METHODS: Medical records of 
CHC patients diagnosed during 2003–2006 at 5 major tertiary-care hospitals in 
Thailand were retrospectively reviewed. Data on CHC-related resource use were col-
lected from diagnosis date to the end of 2007 or the last follow-up date or death date, 
depending on which date came ﬁrst. Using micro-costing method, resource utilization 
categorized as laboratory tests, outpatient visits (OPD), inpatient admissions (IPD), 
procedures and medications were measured for 6 health states of CHC, i.e. CHC, 
compensated cirrhosis (CC), decompensated cirrhosis (DC), hepatocellular carcinoma 
(HCC), liver transplantation at year 1 (LT1), and subsequent years post-transplantation 
(LT2). Costs were estimated using reference prices published by Ministry of Public 
Health and were valued in year 2008 Thai Baht (35 Baht  1 USD). RESULTS: A 
total of 542 patients were identiﬁed with 1578 person-years of follow-up time. OPD 
rate was highest in HCC (7 visits/patient/year). IPD rates increased by 289% from 
CC to DC and 1377% from CC to HCC. Mean lengths of stay per admission were 
9 days in DC and 6 days in HCC. Usage rates of medications for liver complications 
were also increased in DC and HCC. Average annual treatment costs per patient were: 
CHC 243,292 Baht (US$6,951); CC 251,148 Baht (US$7,176); DC 154,686 Baht 
(US$4,420); HCC 171,975 Baht (US$4,914); LT-1, 608,771 Baht (US$17,393) and 
LT2 100,818 Baht (US$2,881). CONCLUSIONS: Resource utilization rates in 
CHC patients increase as the disease progresses. Although inpatient bed charges are 
relatively low and no doctor fee paid for outpatient visits in public hospitals, consump-
tion of these health care resources could have been avoided. Interventions which 
prevent or delay liver disease progressions will profoundly reduce economic burden 
of CHC.
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OBJECTIVES: Constipation is a frequent and possibly debilitating adverse event of 
analgesic treatment with opioids. A new drug combining the opioid oxycodone and 
the opioid antagonist naloxone provides equivalent analgesia to oxycodone alone with 
signiﬁcant improvement in bowel function, as demonstrated in a 12-week randomized 
controlled trial in moderate/severe non-cancer pain (OXN3001). This analysis assessed 
the cost-utility of oxycodone/naloxone vs. oxycodone in Belgium and The Nether-
lands. METHODS: A decision model was developed in MS Excel™. In this model, 
costs (a, Societal perspective) and effects (QALYs) of both strategies were calculated 
over a 3 (base case) to 12-month horizon (no discounting). The proportion of patients 
experiencing opioid-induced constipation (OIC) was derived from the OXN3001 trial. 
Medical resource use for OIC prevention, treatment and complications was collected 
using a Delphi panel including 24 Belgian and Dutch GPs. National tariffs were 
applied to obtain corresponding costs. Utility scores were derived from the SF-36 
questionnaire collected during the OXN3001 trial. Deterministic and probabilistic 
sensitivity analyses were performed. RESULTS: At 3 months, oxycodone/naloxone 
was dominant over oxycodone in The Netherlands, while the incremental cost-
 effectiveness ratio (ICER) was a16,389a/QALY in Belgium (incremental drug cost: 
The Netherlands a115, Belgium 153a; OIC-related savings The Netherlands 136a, 
Belgium a110; QALYs gained: both countries 0.0026). At 12 months, the ICER was 
a12,786/QALY in The Netherlands and a25,421/QALY in Belgium. The proportion 
of patients experiencing at least 1 OIC episode during a 4-week analgesic treatment 
was the most sensitive parameter. A Monte Carlo analysis showed that, assuming a 
willingness to pay threshold of a20,000/QALY (The Netherlands) and a30,000/QALY 
(Belgium), oxydone/naloxone was cost-effective in 58% (The Netherlands) and 63% 
(Belgium) of the 1000 simulations (3-month horizon). CONCLUSIONS: Analgesia 
with oxycodone/naloxone is cost-effective (Belgium) or even dominant (The Netherlands) 
at three months and remains cost-effective up to one year.
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OBJECTIVES: To estimate the resource use and associated cost of treating opioid-
induced constipation (OIC) episodes in cancer patients in Sweden where laxatives 
within current SPC-text have failed. METHODS: Nurses in 3 hospices and 10 home 
care centers across Sweden with experience in caring for cancer patients on opioid 
therapy were selected to participate in an interview series. An interview protocol was 
developed in consultation with an expert. The nurses reported on the frequency of 
OIC episodes, treatment practices and resource use related to constipation. The cost 
components included personnel costs (based on time spent on constipation-related 
tasks), transportation costs (for home care visits) and resource costs. The cost per hour 
for personnel was based on the average salary levels of applicable medical personnel 
in Sweden and overhead cost. The average cost per constipation episode was estimated 
and used to project direct health care cost of OIC in Sweden. RESULTS: The nurses 
reported that on average 24% of patients in home care and 45% of patients in hospices 
had a constipation episode every second week or more often with laxatives in labeled 
doses. The nurses estimated the length of the constipation episode to be between 2–5 
days. Three steps were identiﬁed in the treatment process—increase in dosage of laxa-
tives (100%), provision of suppositories and enemas (40%) and manual disimpaction 
or bowel investigation/contrast X-ray (3% of cases). Nurses spent on average 3.5 
hours ranging across 2 additional visits for treating each episode of OIC. The average 
cost per episode of OIC was estimated to SEK 1700. Direct health care costs of OIC 
in cancer patients who have failed laxatives within current SPC-text, were estimated 
to SEK 40 million per year in Sweden. CONCLUSIONS: Opioid-induced constipation 
in cancer patients in Sweden is associated with signiﬁcant resource use and costs.
PGI17
CONSUMPTION OF HEALTH CARE RESOURCES ASSOCIATED WITH 
CURRENT MANAGEMENT STRATEGIES FOR NON-VARICEAL UPPER 
GASTROINTESTINAL BLEEDING: AN OBSERVATIONAL  
EUROPEAN STUDY
Lanas A1, Tafalla M2, Nuevo J2
11Service of Digestive Diseases, University Hospital, IACS, CIBERehd, Zaragoza, Spain, 
2AstraZeneca, Madrid, Spain
OBJECTIVES: To assess the extent and main drivers of health care resource consump-
tion in patients admitted with non-variceal upper gastrointestinal bleeding (NVUGIB). 
METHODS: This observational, retrospective cohort study (NCT00797641; 
ENERGiB) was conducted in several European countries (Belgium, Greece, Italy, 
Norway, Portugal, Spain and Turkey). Eligible patients were those consecutively 
admitted to hospital (1 October–30 November 2008) who underwent endoscopy for 
overt NVUGIB (haematemesis, melaena or haematochezia, with other clinical/labora-
tory evidence of acute upper gastrointestinal blood loss). Management of patients 
proceeded according to routine care at each centre. During a 30-day follow-up period, 
data on various clinical outcomes were collected from patient medical records. The 
present analysis reports differences between countries in consumption of health care 
resources. RESULTS: A total of 2661 patients (65% men; mean age 67.7 years) were 
enrolled. The mean number of days of hospitalisation (standard deviation [SD]) was 
8.9 (5.9) days. A wide inter-country variation was observed, ranging from 7.4 (4.9) 
days in Turkey to 10.8 (7.5) days in Belgium. Empirical treatment for NVUGIB was 
administered pre-endoscopy in 68.9% of patients (range 35.1% [Belgium] to 88.7% 
[Turkey]), most frequently proton pump inhibitors (PPIs) (66.0% of patients, ranging 
from 32.8% [Belgium] to 87.7% [Turkey]). Therapeutic procedures were performed 
during endoscopy in 35.8% of patients (range 24.9% [Greece] to 40.6% [Belgium]). 
Most commonly performed related procedures were transfusions (any intravenous 
ﬂuid; 84.6% of patients, range 74.0% [Belgium] to 92.3% [Portugal]) and additional 
endoscopies (28.7%, range 12.6% [Turkey] to 53.6% [Belgium]). Treatment for 
NVUGIB was administered post-endoscopy in 93.2% of patients, most commonly 
PPIs (92.6%); a narrow inter-country range was observed. CONCLUSIONS: Manage-
ment of NVUGIB is associated with substantial consumption of health care resources 
in European countries. There is wide variation across Europe; generally, the highest 
rates of resource utilisation are observed in Belgium and the lowest in Turkey.
GASTROINTESTINAL DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To assess the effect of subcutaneous Methylnaltrexone on generic 
Health Related Quality of Life using the EQ-5D index scores in patients on opioid 
therapy for chronic non-malignant pain with opioid-induced constipation. METHODS: 
In this study, 469 subjects were randomized to either methylnaltrexone daily (QD), 
every other day (QOD) dosing or placebo for 4 weeks. Eligibility criteria included an 
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opioid dose of q50 mg oral morphine equivalents/day for q2 weeks and 3 rescue-free 
bowel movements (RFBMs)/week. Rescue laxative use was standardized and allowed 
if needed. Patients completed EQ-5D questionnaire on day 14 and day 28. EQ-5D 
index scores were compared between treatment and placebo groups using analysis of 
covariance, with treatment group as factor and baseline scores as covariate. RESULTS: 
Majority of the patients in the study were female (60%), Caucasian (90%), average 
age of 49 years and back pain (60%) was the most frequently reported pain condition. 
The mean daily baseline morphine equivalent opioid dose was 222 mgs. The mean o 
SD baseline EQ-5D index scores were 0.45 o 0.33 in QD, 0.47 o 0.33 in QOD and 
0.44 o 0.35 in placebo groups respectively. The adjusted mean (o SE) change from 
baseline in index score on day 14 in QD (0.04 o 0.02) and QOD groups (0.06 o 0.02) 
were not statistically signiﬁcant compared to placebo (0.02 o 0.02). At the end of 
the double blind period (day 28), a signiﬁcantly greater change from baseline in 
index scores was detected in the Methylnaltrexone QD dosing group (0.08 vs. 0.01; 
p  0.05) and QOD dosing group (0.08 Vs. 0.01; p  0.05) compared to placebo. 
CONCLUSIONS: Methylnaltrexone SC QD and QOD groups showed a signiﬁcantly 
greater improvement in health related quality of life as measured by the EQ-5D index 
scores at the end of four weeks of therapy compared to placebo.
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OBJECTIVES: Diagnostic self-administered questionnaires for GERD are widely used        
and provide brief and valid measure of gastrointestinal symptoms. Beyond evaluation 
of symptoms and disease severity they are considered as proxy for Quality of Life 
(QoL) and other patients related outcome. Present study should examine relationship 
with patients’ ability carrying out daily activities. METHODS: Randomly selected  
patients (n  623) with chronic GERD symptoms treated by German ofﬁce-based 
physicians in routine clinical care completed self-administered instruments for produc-
tivity (WPAI-GERD), and symptoms (RDQ, GIS, GSRS) in assessing the response to 
treatment. WPAI-GERD includes a visual analogue scale (0–10) to rate the impairment 
of the ability to do regular daily activities in the preceding week. Reported reduction 
of daily activities was split between patients with and without, and compared using 
logistic regression, accounting for the potential confounders age and PPI-medication. 
RESULTS: Only one subscale from each three examined instrument—“diarrhoea”        
(GSRS), “impact” (GIS) and “dyspepsia” (RDQ)—were associated with reduced pro-
ductivity in daily activities in the logistic model (OR: 1.29, 3.36 and 1.46). Mean 
scores were 1.58 vs. 2.17 for subscale “diarrhoea”, 1.38 vs. 1.91 for subscale “impact” 
and 0.61 vs. 1.61 for subscale “dyspepsia”. Prescribed PPI-medication turned out to 
be independent, the odds of reduced productivity decreased with age slightly but sig-
niﬁcantly (OR 0.98). Both GSRS and RDQ have validated summary scores. “GSRS 
total” and “RDQ GERD” interacted strong with the dependent variable in the model 
(OR: 2.08 resp. 1.34). CONCLUSIONS: Validated diagnostic questionnaires for    
GERD are connected with patients’ ability carrying out daily activities. However 
subscales insufﬁciently reﬂect the perceived impact on daily life measured by reduction 
in daily activities. Generic or disease speciﬁc QoL instruments should be used in addi-
tion for a comprehensive understanding of patients’ burden in clinical practice.
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OBJECTIVES: To assess the effect of subcutaneous Methylnaltrexone on patient 
reported constipation speciﬁc quality of life. METHODS: In a double blind study 469 
subjects on opioid therapy for chronic non-malignant pain and opioid-induced con-
stipation were randomized to either methylnaltrexone QD or QOD dosing or placebo 
for 4 weeks and 460 received at least 1 dose. Subjects were eligible if they had an 
opioid dose of q50 mg oral morphine equivalents/day for q2 weeks and 3 rescue free 
bowel movements (RFBMs)/week. Patients reported constipation speciﬁc quality of 
life using the Patient Assessment of Constipation—Quality of Life (PAC-QOL) ques-
tionnaire which is a validated 28—item questionnaire assessing physical discomfort 
(4 items), psychosocial discomfort (8 items), worries and concerns (11 items) and 
treatment satisfaction (5 items) on a 5-point Likert scale. Higher scores indicate poorer 
QOL. Change from baseline in mean domain and total scores were compared between 
methylnaltrexone and placebo arms on day 28 using analysis of covariance, with 
treatment group as factor and baseline score as covariate. RESULTS: Majority of the 
patients in the study were female (60%), Caucasian (90%), average age was 49 years 
and reported back pain (60%). At the end of the double blind period (day 28), a 
 signiﬁcantly greater improvement was detected in the methylnaltrexone QD dosing 
group compared to placebo for: physical discomfort (0.81 vs. 0.39;p  0.001), 
psychosocial discomfort (0.51 vs. 0.32; p  0.05), worries and concerns (0.69 vs. 
0.38; p  0.001), satisfaction (0.96 vs.0.48; p  0.001) and overall PAC-QOL 
score (0.74 vs. 0.39; p  0.001). Signiﬁcantly greater improvement in physical dis-
comfort (0.60 vs. 0.39; p  0.05), satisfaction (0.79 vs. 0.48; p  0.05) and the 
overall PAC-QOL scores (0.59 vs. 0.39; p  0.05) were found in the methylnal-
trexone QOD dosing group compared to placebo. CONCLUSIONS: Subcutaneous 
methylnaltrexone showed a signiﬁcantly greater improvement in patient reported 
constipation speciﬁc quality of life compared to placebo.
GASTROINTESTINAL DISORDERS – Health Care Use & Policy Studies
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OBJECTIVES: This analysis evaluates economic impact of compliance with guidelines         
for treatment of Chronic Hepatitis C (CHC), where treatment decision is based on 
results of quantitative HCV RNA test (qRNA). METHODS: Retrospective insurance  
company database analysis of 879 patients with CHC was performed. There were 334 
patients tested for qRNA during the period from 1.1.2005 till 31.8.2008. Decision 
tree model was developed to evaluate treatment costs when qRNA test is used for 
treatment termination. RESULTS: In 2004 national guidelines for CHC were published,        
which recommended examination of qRNA before and 12 weeks after treatment ini-
tiation to detect early virological response (EVR) and treatment termination in case 
of negative results of EVR. In 334 patients there were 611 qRNA tests performed in 
total (150 patients had only 1 qRNA, 113 had 2 qRNA, in 55 there were 3 consecutive 
qRNA performed, 16 patients had more then 4 consecutive qRNA tests). In our model, 
omission of EVR evaluation was deﬁned as no or only one quantitative HCV RNA 
test or gap between two qRNA tests longer then 48 weeks. Omission of EVR evaluation 
was detected in 166 patients. In a decision tree model taking into account EVR results 
(followed by appropriate treatment termination) it was calculated that treatment cost 
in this group of 166 patients could be a4,013,880, while the treatment of the same 
group with omission of EVR evaluation would be a4,870,440. CONCLUSIONS: In 
analyzed group of 334 patients with HCV, there were almost 50% of cases were tre-
atment termination could not be evaluated in accordance with valid guidelines, because 
of inappropriate performance of quantitative HCV RNA tests. Calculated savings are 
a856,560 in this group of patients. Preparation and implementation of clinical practice 
guidelines in national health and drug policy could have cost saving effect.
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OBJECTIVES: Surgical management of Haemorrhoidal Disease includes Milligan-      
Morgan (MM) haemorrhoidectomy and stapled haemorrhoidopexy (PPH, Procedure 
for Prolapse and Haemorrhoids), which excises prolapsing tissues, whilst maintaining 
physiological functioning of haemorrhoidal plexus. Scope of work was to develop an 
HTA Report evaluating PPH in terms of clinical, ethical, social, organizational and 
economic impact. METHODS: Literature search on Medline/PubMed, Embase data-     
bases; analysis of the clinical course for PPH vs. MM at 3 Hospitals in Lombardia 
Region: bottom-up costing of the surgical course (surgery, hospital admission) and of 
the global course (clinical evaluation, surgical course, follow-up phase). Medical 
resources, collected by structured questionnaires, were valued (Euro 2008) on the basis 
of full hospital costs (personnel, operating theatre, hospital stay), regional outpatient 
tariffs (diagnostics), market prices (drugs, medical devices) and average per-capita 
Gross Domestic Product (working days). RESULTS: Cost analysis of the surgical     
course showed Hospital direct costs per patient/case of a2306 and a1558 respectively 
for PPH and MM (difference a748); and for the global course a2532 for PPH and 
a1781 for MM; these values exceed the ﬁxed regional DRG 158 tariff (a1209) for 
hospital reimbursement. Sensitivity analyses, based on published meta-analysis data, 
conﬁrmed the robustness of basecase results. Average regained productivity was esti-
mated to be 11.3 working days/year, with a potential social beneﬁt of a752/patient. 
The budget impact analysis, based on the difference of cost (a748) between the surgical 
courses to be applied as an extra-tariff for PPH, and on regional statistics for the 
intervention, estimated an extra-cost ranging from 1.7% to 16% over the current 
regional funding for the procedure of a9.24 mio/year.  CONCLUSIONS: Analysis of  
hospital disease management courses for haemorrhoidal disease showed the inade-
quacy of current funding for both surgical procedures, and provided an estimation of 
the effect of suggested tariff increase in order to adequately fund the local providers 
of Lombardia.
